Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
TEVA

TEVA - Teva Pharmaceutical Industries Ltd Stock Price, Fair Value and News

$34.63+0.07 (+0.20%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

29/100

TEVA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

29/100

TEVA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TEVA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TEVA Price Action

Last 7 days

1.3%

Last 30 days

-4.5%

Last 90 days

21.2%

Trailing 12 Months

95.5%

TEVA RSI Chart

TEVA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TEVA Valuation

Market Cap

40.0B

Price/Earnings (Trailing)

25.59

Price/Sales (Trailing)

2.31

EV/EBITDA

10.95

Price/Free Cashflow

23.36

TEVA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TEVA Fundamentals

TEVA Revenue

Revenue (TTM)

17.3B

Rev. Growth (Yr)

2.34%

Rev. Growth (Qtr)

-15.47%

TEVA Earnings

Earnings (TTM)

1.6B

Earnings Growth (Yr)

72.43%

Earnings Growth (Qtr)

-23.2%

TEVA Profitability

EBT Margin

7.87%

Return on Equity

19.01%

Return on Assets

3.91%

Free Cashflow Yield

4.28%

TEVA Investor Care

Dividend Yield

0%

Dividend/Share (TTM)

0

Shares Dilution (1Y)

1.58%

Diluted EPS (TTM)

1.34

TEVA Alerts

  • 6 major insider sales recently.
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202617.3B000
202516.6B16.6B16.8B17.3B
202416.0B16.3B16.8B16.5B
202314.9B15.0B15.3B15.8B
202215.6B15.4B15.1B14.9B
202116.3B16.3B16.2B15.9B
202017.1B16.8B16.7B16.7B
201917.5B17.1B16.8B16.9B
201821.7B20.5B19.3B18.3B
201722.7B23.4B23.5B22.4B
201619.5B19.6B20.3B21.9B
201520.3B20.2B19.9B19.7B
201420.4B20.5B20.5B20.3B
201320.2B20.1B20.2B20.3B
201219.2B20.0B20.6B20.3B
2011017.0B17.1B18.3B
Get all data in R, Python etc through our Historical Stock Data APIs

About Teva Pharmaceutical Industries Ltd

TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
 CEO
 WEBSITEtevapharm.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES34004

Teva Pharmaceutical Industries Ltd Frequently Asked Questions

TEVA is the stock ticker symbol of Teva Pharmaceutical Industries Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Teva Pharmaceutical Industries Ltd is 40.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, TEVA's PE ratio (Price to Earnings) is 25.59 and Price to Sales (PS) ratio is 2.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TEVA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Teva Pharmaceutical Industries Ltd has provided -0.042 (multiply by 100 for percentage) rate of return.